*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated 28 October 2013 (the "**Prospectus**") issued by PW Medtech Group Limited (the "**Company**").*

This announcement is for information purposes only and does not constitute an offer or an invitation by any person to acquire, purchase or subscribe for securities of the Company.

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the "**U.S. Securities Act**"). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act. There will be no public offer of securities in the United States.*

PW MEDTECH GROUP LIMITED
普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 01358)

FULL EXERCISE OF OVER-ALLOTMENT OPTION

The Company announces that the Over-allotment Option has been fully exercised by the Sole Global Coordinator on behalf of the International Underwriter on 18 November 2013 in respect of 60,000,000 Shares, representing 15% of the Offer Shares initially available under the Global Offering. The Over-allotment Shares will be sold by the Company at HK$3.18 per Share (exclusive of brokerage, SFC transaction levy and Stock Exchange trading fee, if any), being the Offer Price under the Global Offering.

The Company announces that the Over-allotment Option has been fully exercised by the Sole Global Coordinator on behalf of the International Underwriter on 18 November 2013 in respect of 60,000,000 Shares (the "**Over-allotment Shares**"), representing 15% of the Offer Shares initially available under the Global Offering.

The Over-allotment Shares will be sold by the Company at HK$3.18 per Share (exclusive of brokerage, SFC transaction levy and Stock Exchange trading fee, if any), being the Offer Price under the Global Offering. The Over-allotment Shares will be used to cover over-allocations in the International Offering.

Approval for the listing of and permission to deal in the Over-allotment Shares has already been granted by the Listing Committee of the Stock Exchange.

The shareholding structure of the Company immediately before and immediately after the sale of the Over-allotment Shares by the Company is as follows:

A. IMMEDIATELY BEFORE THE SALE OF THE OVER-ALLOTMENT SHARES

Shareholders	Number of Shares	Approximate percentage of the Company's issued share capital *(%)*
Cross Mark	547,061,863	34.19
WP X	327,148,418	20.45
Right Faith	232,256,544	14.52
Sparkle Wealthy	93,533,175	5.84
Public Shareholders	400,000,000	25
Total	1,600,000,000	100

B. IMMEDIATELY AFTER THE SALE OF THE OVER-ALLOTMENT SHARES

Shareholders	Number of Shares	Approximate percentage of the Company's issued share capital *(%)*
Cross Mark	547,061,863	32.96
WP X	327,148,418	19.71
Right Faith	232,256,544	13.99
Sparkle Wealthy	93,533,175	5.63
Public Shareholders	460,000,000	27.71
Total	1,660,000,000	100

The net proceeds of approximately HK$184 million (exclusive of brokerage, SFC transaction levy and Stock Exchange trading fee) from the issue and sale of the Over-allotment Shares by the Company will be used by the Company for the same purposes as set out in the section headed "Future plans and use of proceeds — Use of proceeds" in the Prospectus on a pro-rata basis.

The Company continues to comply with the public float requirements under Rule 8.08(1)(a) of the Listing Rules.

By order of the Board of Directors
PW Medtech Group Limited
Lin Junshan
Chairman

Hong Kong, 18 November 2013

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Jiang Liwei as executive Director; Mr. Lin Junshan, Ms. Yue'e Zhang and Mr. Feng Dai as non-executive Directors; Mr. Zhang Xingdong, Mr. Wang Xiaogang and Mr. Chen Geng as independent non-executive Directors.